

News Release

Rosetta Genomics to Host Business Update and Six Month Financials Conference Call on October 27, 2015

PHILADELPHIA, PA. and REHOVOT, Israel (October 20, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.S. stock market on Monday, October 26, 2015, the Company will file its financial results for the six months ended June 30, 2015 on Form 6-K with the U.S. Securities and Exchange Commission (“SEC”). The Form 6-K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6-K will be available at www.sec.gov and at www.rosettagenomics.com.

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Tuesday, October 27, 2015 at 10:00 a.m. Eastern time to provide an update on the Company’s business and respond to questions.

Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 63154375. The call is also being webcast, and can be accessed on the investor relations section of the Company’s website at www.rosettagenomics.com.

A telephone replay will be available through November 2, 2015 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 63154375. The webcast will be available on the Company’s website for 30 days following the completion of the call.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including but not limited to statements relating to the timing regarding Rosetta’s publishing its financials for the first half of 2015, as well as the timing and contents of a possible business update call are forward-looking statements for the purposes of the safe harbor provisions under The

Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contacts:

Rosetta Genomics

Ken Berlin, President & CEO

(609) 419-9003

investors@rosettagenomics.com

Investor Contacts:

LHA

Anne Marie Fields

(212) 838-3777

afields@lhai.com

or

Bruce Voss

(310) 691-7100

bvoss@lhai.com

#